Khanafer Ali, Palmarola Pablo Albiña, Hajiyev Kamran, von Gottberg Philip, Filioglo Andrei, Forsting Michael, Henkes Hans
Neuroradiologische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
Department of Neurosurgery, Institute of Emergency Care, Chisinau, Moldova.
Front Neurol. 2025 Jun 24;16:1605808. doi: 10.3389/fneur.2025.1605808. eCollection 2025.
Flow-diverter (FD) stents have become an established treatment for intracranial aneurysms in recent years, but their use for aneurysms in distal cerebral vessels with small caliber remains controversial. This study reports our single-center experience in using hydrophilic polymer-coated (HPC) p48 MW FDs with prasugrel single antiplatelet therapy (SAPT) to treat ruptured and unruptured aneurysms arising from small-caliber vessels (≤ 2 mm).
A prospectively maintained database was retrospectively reviewed to identify all cases of intracranial aneurysms arising from small-caliber vessels (≤ 2 mm) treated with the p48 MW HPC device under SAPT (Prasugrel). The clinical presentation and outcomes, periprocedural and postprocedural complications, and degree of occlusion at follow-up (FU) were evaluated.
A total of 62 patients (70.7% women) with 65 aneurysms were treated. Two patients (3.2%) experienced complications associated with FD use. No cases of aneurysm rupture or hemorrhagic complications associated with antiplatelet therapy or FD treatment were recorded. The rate of complete occlusion was 71.9% in the early FU period (3-6 months) and 86.1% in the initial 12-month period.
p48 MW HPC FDs with prasugrel SAPT showed high safety in the treatment of ruptured and unruptured aneurysms arising from small-caliber vessels (≤ 2 mm), and high occlusion rates at early- and mid-term FU.
近年来,血流导向(FD)支架已成为颅内动脉瘤的既定治疗方法,但其在小口径大脑远端血管动脉瘤治疗中的应用仍存在争议。本研究报告了我们单中心使用亲水性聚合物涂层(HPC)p48 MW FD联合普拉格雷单一抗血小板治疗(SAPT)治疗小口径血管(≤2毫米)破裂和未破裂动脉瘤的经验。
回顾性分析前瞻性维护的数据库,以确定所有在SAPT(普拉格雷)下使用p48 MW HPC装置治疗的小口径血管(≤2毫米)颅内动脉瘤病例。评估临床表现和结果、围手术期和术后并发症以及随访(FU)时的闭塞程度。
共治疗62例患者(女性占70.7%),动脉瘤65个。2例患者(3.2%)出现与使用FD相关的并发症。未记录到与抗血小板治疗或FD治疗相关的动脉瘤破裂或出血并发症病例。早期FU期(3 - 6个月)完全闭塞率为71.9%,最初12个月时为86.1%。
p48 MW HPC FD联合普拉格雷SAPT在治疗小口径血管(≤2毫米)破裂和未破裂动脉瘤时显示出高安全性,且在早期和中期FU时有较高的闭塞率。